Provided by Tiger Trade Technology Pte. Ltd.

Corcept Therapeutics

33.87
-0.1700-0.50%
Post-market: 33.870.00000.00%19:52 EST
Volume:1.23M
Turnover:41.47M
Market Cap:3.60B
PE:41.30
High:34.18
Open:33.26
Low:32.99
Close:34.04
52wk High:117.33
52wk Low:28.66
Shares:106.37M
Float Shares:86.88M
Volume Ratio:0.97
T/O Rate:1.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.8200
EPS(LYR):0.8200
ROE:15.01%
ROA:3.34%
PB:5.56
PE(LYR):41.30

Loading ...

Corcept's Hypercortisolism Sales Outlook Seen as Unrealistic -- Market Talk

Dow Jones
·
Dec 17, 2025

Oil Prices Sink To $55, Lowest In Nearly 5 Years: What's Moving Markets Tuesday?

Benzinga
·
Dec 17, 2025

UBS Initiates Corcept Therapeutics at Neutral With $95 Price Target

MT Newswires Live
·
Dec 16, 2025

Corcept Therapeutics Inc : UBS Initiates Coverage With Neutral Rating and Target Price $95

THOMSON REUTERS
·
Dec 16, 2025

Corcept Therapeutics Initiated at Neutral by UBS

Dow Jones
·
Dec 16, 2025

Corcept Therapeutics CEO Joseph K. Belanoff Reports Disposal of Common Shares

Reuters
·
Dec 04, 2025

Corcept Therapeutics (CORT): Assessing Valuation After Revenue Outlook Revision and Growth in Korlym Prescriptions

Simply Wall St.
·
Nov 29, 2025

Corcept Therapeutics Chief Development Officer William Guyer Reports Sale of Common Shares

Reuters
·
Nov 27, 2025

Corcept Therapeutics Price Target Maintained With a $145.00/Share by HC Wainwright & Co.

Dow Jones
·
Nov 25, 2025

Chief Development Officer William Guyer Reports Disposal of Corcept Therapeutics Common Shares

Reuters
·
Nov 08, 2025

Corcept Therapeutics CEO Joseph K. Belanoff Reports Disposal of Common Shares

Reuters
·
Nov 06, 2025

Sean Maduck, President of Corcept Endocrinology, Reports Disposal of Corcept Therapeutics Common Shares

Reuters
·
Nov 06, 2025

H.C. Wainwright Reaffirms Their Buy Rating on Corcept Therapeutics (CORT)

TIPRANKS
·
Nov 05, 2025

Stock Track | Corcept Therapeutics Soars 5.61% as Analyst Maintains Buy Rating Amid Recent Pullback

Stock Track
·
Nov 05, 2025

Truist Financial Sticks to Their Buy Rating for Corcept Therapeutics (CORT)

TIPRANKS
·
Nov 05, 2025

Stock Track | Corcept Therapeutics Plunges 9.83% Pre-market on Q3 Revenue Miss and Lowered 2025 Guidance

Stock Track
·
Nov 05, 2025

Does Corcept Therapeutics’ Recent 21% Pullback Signal a Fresh Opportunity in 2025?

Simply Wall St.
·
Nov 05, 2025

Stock Track | Corcept Therapeutics Plunges 7.24% After Q3 Revenue Miss and Lowered Guidance

Stock Track
·
Nov 05, 2025

GUIDANCE: (CORT) Corcept Therapeutics Modifies 2025 Revenue Range To $800M-$850M, vs. FactSet Est of $852.6M

MT Newswires Live
·
Nov 05, 2025

Earnings Flash (CORT) Corcept Therapeutics Posts Q3 EPS $0.16, vs. FactSet Est of $0.13 by Four Analysts

MT Newswires Live
·
Nov 05, 2025